Why Is Moderna Stock Trading Higher On Monday?
Why Is Moderna Stock Trading Higher On Monday?
Monday, Moderna, Inc.'s (NASDAQ:MRNA) manufacturing facility in Laval, Quebec, received a Drug Establishment License (DEL) from Health Canada.
星期一，Moderna, Inc.”s（納斯達克股票代碼：MRNA）位於魁北克省拉瓦爾的製造工廠獲得了加拿大衛生部頒發的藥品機構許可證（DEL）。
This certification affirms the facility's compliance with safety and quality standards, authorizing it to produce drug substances.
該認證確認了該設施符合安全和質量標準，並授權其生產藥物物質。
This key milestone enables Moderna's Canadian manufacturing site to become fully operational, bringing the company closer to ensuring a reliable and onshore supply of mRNA vaccines within Canada.
這一關鍵里程碑使Moderna的加拿大製造基地得以全面運營，使該公司更接近於確保加拿大境內mRNA疫苗的可靠陸上供應。
With the License in place, the facility will proceed with the final qualification process, positioning it to domestically manufacture a portfolio of mRNA vaccines against respiratory viruses beginning in 2025, including COVID-19 and, contingent on approval by Health Canada, respiratory syncytial virus (RSV), and seasonal influenza.
許可證到位後，該設施將進入最終認證程序，使其能夠從2025年開始在國內生產針對呼吸道病毒的mRNA疫苗組合，包括 COVID-19 以及呼吸道合胞病毒（RSV）和季節性流感（視加拿大衛生部的批准而定）。
Also Read: Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
另請閱讀：動物研究顯示，Moderna的研究型Mopox疫苗比目前批准的疫苗更有效
"This is a significant achievement in our efforts to bring certified end-to-end mRNA manufacturing capabilities to Canada and is the first of our manufacturing sites outside the U.S. to reach this milestone," said Stéphane Bancel, Chief Executive Officer of Moderna. "We look forward to continuing our work with the Government of Canada to support the national supply of vital respiratory vaccines."
Moderna首席執行官Stephane Bancel表示：「這是我們在爲加拿大提供經過認證的端到端mRNA製造能力方面取得的一項重大成就，也是我們在美國以外第一個達到這一里程碑的製造基地。」「我們期待繼續與加拿大政府合作，支持全國重要呼吸道疫苗的供應。」
"This is another landmark in Moderna's long-term strategic partnership with the Government of Canada to provide onshore respiratory vaccine manufacturing capabilities and support national pandemic readiness," said Roger Ngassam, Laval Manufacturing Site Head, Moderna Canada. "This platform will be the foundation for enabling the manufacturing of multiple mRNA vaccines right here in Canada."
加拿大摩德納拉瓦爾製造基地負責人羅傑·恩加薩姆表示：「這是Moderna與加拿大政府建立長期戰略合作伙伴關係的又一個里程碑，旨在提供陸上呼吸道疫苗生產能力並支持國家疫情防範。」「該平台將成爲加拿大生產多種mRNA疫苗的基礎。」
This milestone also builds on Moderna's existing manufacturing footprint, including key U.S. facilities and facilities under construction in Australia and the U.K.
這一里程碑還建立在 Moderna 現有的製造足跡基礎上，包括在澳大利亞和英國建設的主要美國設施和設施。
Recently, the FDA granted emergency use authorization for updated mRNA COVID-19 vaccines (2024-2025 formula) from Moderna and Pfizer Inc (NYSE:PFE)/ BioNTech SE (NASDAQ:BNTX).
最近，美國食品藥品管理局批准了莫德納和輝瑞公司（紐約證券交易所代碼：PFE）/BioNTech SE（納斯達克股票代碼：BNTX）更新的mRNA COVID-19 疫苗（2024-2025年配方）的緊急使用授權。
Price Action: MRNA stock is up 6.70% at $77.77 at the last check Monday.
價格走勢：在週一的最後一次檢查中，MRNA股票上漲6.70％，至77.77美元。
- Pembina Strikes Major Deal To Boost Oil And Gas Infrastructure: Details.
- 彭比納達成重大協議以促進石油和天然氣基礎設施：詳情。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。